Next Article in Journal / Special Issue
Strategy for Treating Motor Neuron Diseases Using a Fusion Protein of Botulinum Toxin Binding Domain and Streptavidin for Viral Vector Access: Work in Progress
Previous Article in Journal
The Cyanobacteria Derived Toxin Beta-N-Methylamino-L-Alanine and Amyotrophic Lateral Sclerosis
Previous Article in Special Issue
Targeted Secretion Inhibitors—Innovative Protein Therapeutics
Toxins 2010, 2(12), 2851-2871; doi:10.3390/toxins2122851

Spider-Venom Peptides as Therapeutics

Institute for Molecular Bioscience, The University of Queensland, St Lucia, Queensland, 4072, Australia
* Author to whom correspondence should be addressed.
Received: 16 November 2010 / Revised: 17 December 2010 / Accepted: 17 December 2010 / Published: 20 December 2010
(This article belongs to the Special Issue Toxins as Therapeutics)
View Full-Text   |   Download PDF [416 KB, uploaded 20 December 2010]   |   Browse Figures


Spiders are the most successful venomous animals and the most abundant terrestrial predators. Their remarkable success is due in large part to their ingenious exploitation of silk and the evolution of pharmacologically complex venoms that ensure rapid subjugation of prey. Most spider venoms are dominated by disulfide-rich peptides that typically have high affinity and specificity for particular subtypes of ion channels and receptors. Spider venoms are conservatively predicted to contain more than 10 million bioactive peptides, making them a valuable resource for drug discovery. Here we review the structure and pharmacology of spider-venom peptides that are being used as leads for the development of therapeutics against a wide range of pathophysiological conditions including cardiovascular disorders, chronic pain, inflammation, and erectile dysfunction.
Keywords: spider venom; peptide; therapeutics; drugs; drug discovery; cystine knot spider venom; peptide; therapeutics; drugs; drug discovery; cystine knot
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Saez, N.J.; Senff, S.; Jensen, J.E.; Er, S.Y.; Herzig, V.; Rash, L.D.; King, G.F. Spider-Venom Peptides as Therapeutics. Toxins 2010, 2, 2851-2871.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert